Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANYELZA vs SYLVANT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.
Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.
Neuroblastoma: in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.
Treatment of multicentric Castleman disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,Off-label: Treatment of cytokine release syndrome, Castleman disease in HIV-positive or HHV-8-positive patients, and other IL-6-driven conditions.
1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.
11 mg/kg intravenously every 3 weeks, administered over 1 hour.
Terminal elimination half-life is approximately 29 days (range 25–35 days) at steady state, supporting a weekly dosing schedule for maintaining therapeutic concentrations.
Terminal half-life ~21 days (range 14–28 days) at steady state; supports every-3-week dosing.
Metabolized via catabolic pathways into small peptides and amino acids; no major CYP450 involvement.
Siltuximab is a monoclonal antibody; its metabolism is not typical. It is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. No specific metabolic enzymes are involved.
Renal elimination accounts for approximately 80% of the administered dose as unchanged drug; the remaining 20% is excreted via the biliary/fecal route.
Renal (minimal as intact Ig G), primarily catabolized to amino acids; no significant biliary/fecal elimination.
Approximately 99% bound to plasma proteins, primarily albumin and low-density lipoproteins.
No specific protein binding; Ig G4 monoclonal antibody does not bind significantly to plasma proteins.
Volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the plasma compartment.
Vd ~6.0 L (0.08 L/kg for 70 kg adult); primarily confined to vascular space and interstitial fluid.
Only available as intravenous formulation; bioavailability is 100% by definition for IV administration, with no oral or other route available.
IV administration: 100% bioavailable; no other routes approved.
No dose adjustment recommended for mild to moderate renal impairment. Severe renal impairment or end-stage renal disease: not studied, use with caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Severe hepatic impairment (Child-Pugh C): not studied, use with caution.
No formal studies in hepatic impairment. Use with caution in patients with moderate to severe impairment (Child-Pugh B or C).
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; monitor for toxicity due to potential age-related renal or hepatic impairment.
No specific dose adjustment recommended; select dose with caution due to higher frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.
WARNING: SERIOUS INFUSION-RELATED REACTIONS AND NEUROTOXICITY. Premedicate for infusion-related reactions. Monitor for and manage neurotoxicity (severe neuropathic pain, transverse myelitis, posterior reversible encephalopathy syndrome).
None.
Infusion-related reactions (hypotension, urticaria, bronchospasm); neurotoxicity (severe pain, transverse myelitis, PRES); myelosuppression; capillary leak syndrome; infections; electrolyte abnormalities; fever; hypersensitivity reactions; interference with tumor response assessment.
Risk of serious infections: Evaluate for active infections prior to initiating therapy; monitor for infections during treatment.,Hypersensitivity reactions: Infusion-related reactions may occur; premedicate and monitor during infusion.,Hematologic effects: Neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts.,Hepatotoxicity: Elevations of liver enzymes have been reported; monitor liver function.,Immunogenicity: Anti-drug antibodies may develop and affect efficacy or safety.,Vaccinations: Live vaccines should not be administered during treatment.
None known.
Known severe hypersensitivity to siltuximab or any of its excipients.,Active severe infections until infection is controlled.
No specific food interactions are established for DANYELZA. Maintain adequate hydration and nutrition as tolerated. Avoid grapefruit and grapefruit juice if taking concomitant medications that are CYP3A4 substrates, though DANYELZA itself is not metabolized by CYP450 enzymes.
No clinically significant food interactions have been reported. Take with or without food as tolerated.
Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal toxicity including malformations and growth retardation. Advise females of reproductive potential of the potential risk to a fetus. Use effective contraception during treatment and for at least 2 months after the last dose.
SYLVANT (siltuximab) is a monoclonal antibody (Ig G1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Animal studies have shown no evidence of teratogenicity in cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, there are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (IL-6 inhibition), there is a potential risk of fetal harm due to interference with normal immune development and hematopoiesis. Therefore, SYLVANT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 2 months after the last dose.
It is not known whether siltuximab is excreted in human milk. However, maternal Ig G is known to be present in breast milk, and monoclonal antibodies can be excreted in low amounts. The M/P ratio is not available. The effects on the breastfed infant and on milk production are unknown. Because of the potential for adverse reactions in nursing infants from siltuximab, breastfeeding should be discontinued during treatment and for at least 90 days after the last dose.
Dosing adjustments during pregnancy are not established. Use only if potential benefit justifies potential risk to the fetus. Consider delaying treatment until after delivery if feasible.
No specific dose adjustments are recommended for SYLVANT during pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may occur, but no data are available to guide adjustments. The drug should be used with caution, and the dose should be guided by clinical response and tolerability.
DANYELZA (naxitamab) is a GD2-binding monoclonal antibody for relapsed/refractory high-risk neuroblastoma. Premedicate with antihistamines, acetaminophen, and corticosteroids to mitigate infusion-related reactions. Monitor for severe pain, which is a known adverse effect; may require opioid analgesics. Closely monitor for hypotension and bronchospasm during infusion. Administer in a setting equipped to manage anaphylaxis.
SYLVANT (siltuximab) is an IL-6 antagonist indicated for idiopathic multicentric Castleman disease (MCD). Monitor for infections due to immunosuppression; do not administer live vaccines. Infusion reactions possible; premedicate with antihistamines/acetaminophen if needed. Assess baseline hepatic function, as transaminase elevations may occur. Discontinue if severe infusion reaction or anaphylaxis.
DANYELZA is given intravenously over several hours, typically on consecutive days.,You may experience severe pain during or after infusion; report it immediately.,Common side effects include fever, nausea, vomiting, and low blood pressure.,Serious allergic reactions can occur; inform your doctor if you develop hives, trouble breathing, or swelling.,Avoid driving or operating machinery if you feel dizzy or tired after treatment.,Notify your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.
Report signs of infection (fever, chills, sore throat) immediately.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for 3 months after.,Notify your doctor if you experience symptoms of infusion reaction (headache, nausea, dizziness, rash).,Regular blood tests will be required to monitor liver function and blood counts.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANYELZA vs SYLVANT, answered by our medical review team.
DANYELZA is a Monoclonal Antibody Antineoplastic that works by Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.. SYLVANT is a Monoclonal Antibody Antineoplastic that works by Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANYELZA and SYLVANT depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANYELZA is: 1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.. The standard adult dose of SYLVANT is: 11 mg/kg intravenously every 3 weeks, administered over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DANYELZA and SYLVANT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DANYELZA is classified as Category C. Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal. SYLVANT is classified as Category C. SYLVANT (siltuximab) is a monoclonal antibody (IgG1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Anim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.